Omalizumab biosimilar - Kashiv BioSciences
Alternative Names: ADL-018Latest Information Update: 30 Jul 2024
At a glance
- Originator Adello Biologics
- Developer Kashiv BioSciences
- Class Antiallergics; Antiasthmatics; Monoclonal antibodies; Skin disorder therapies
- Mechanism of Action IgE receptor antagonists
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
- New Molecular Entity No
- Available For Licensing Yes - Asthma
Highest Development Phases
- Phase III Chronic urticaria
- Phase I Asthma
Most Recent Events
- 25 Jul 2024 Kashiv BioSciences completes enrolment in its phase III trial for Chronic Urticaria (In adults, In the elderly, Treatment-experienced) in the Europe, Jordan, USA, and India (SC) (NCT05774639)
- 02 Jul 2024 Amneal Pharmaceuticals in-licenses Omalizumab biosimilar from Kashiv Biosciences
- 03 Oct 2023 Omalizumab biosimilar - Kashiv Biosciences licensed to Alvotech for development and commercialisation in the United Kingdom, Australia, European Union, Canada and New Zealand